New molecular targeted therapies, diagnostics, genomics and proteomics are changing the face of cancer, spurring exciting opportunities — and also new challenges — for this healthcare sector worldwide, especially in China. Nearly 2,000 individual molecules for the treatment of cancer are under development — a measure of the industry’s determination and ongoing commitment to finding new and innovative treatments for cancer. Even if only one-third of these indications are ultimately approved, treatment options will be enormously expanded for many tumor types over the next 10 to 20 years. At the new age of targeted therapy, anti-cancer depends more and more on international collaborations, as well as industry and academia partnering. By three years of proven track record of World Pharmaceutical (China) Summit, INNCH International will launch the China Oncology Congress 2011 to provide more platforms for anti-cancer leaders learning and networking here in China.